Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors
Autore:
Acosta, EP; Kakuda, TN; Brundage, RC; Anderson, PL; Fletcher, CV;
Indirizzi:
Univ Minnesota, Coll Pharm, Dept Expt & Clin Pharmacol, Acad Hlth Sci Ctr,Minneapolis, MN 55455 USA Univ Minnesota Minneapolis MN USA 55455 Sci Ctr,Minneapolis, MN 55455 USA
Titolo Testata:
CLINICAL INFECTIOUS DISEASES
, volume: 30, anno: 2000, supplemento:, 2
pagine: S151 - S159
SICI:
1058-4838(200006)30:<S151:POHIVT>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
PLASMA DRUG CONCENTRATIONS; RITONAVIR PLUS SAQUINAVIR; HIV-INFECTED PATIENTS; ALPHA(1)-ACID GLYCOPROTEIN; REVERSE-TRANSCRIPTASE; NELFINAVIR MESYLATE; ZIDOVUDINE ZDV; SHORT-TERM; IN-VITRO; INDINAVIR;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
37
Recensione:
Indirizzi per estratti:
Indirizzo: Fletcher, CV Univ Minnesota, Coll Pharm, Dept Expt & Clin Pharmacol, Acad Hlth Sci Ctr,7-151 Weaver Densford Hall,308 Harvard St SE, Minneapolis, MN 55455 USA Univ Minnesota 7-151 Weaver Densford Hall,308 Harvard St SE Minneapolis MN USA 55455
Citazione:
E.P. Acosta et al., "Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors", CLIN INF D, 30, 2000, pp. S151-S159

Abstract

Many factors are involved in the success or failure of antiretroviral therapy. Recent data suggest that there are significant differences in drug absorption and disposition for the protease inhibitor class of antiretroviral drugs, and relationships between plasma concentrations and their antiviral effect have been described. Consequently, the issue of whether therapeutic drug monitoring should be employed for patients receiving treatment with these drugs has arisen. Several criteria must be met before a drug is considered a candidate for therapeutic drug monitoring. These criteria include pharmacological, clinical, and analytic components. Although not all the necessary criteria have yet been met, some of these components have been defined, and additional data are being generated. However, prospectively designed clinical trials must be completed to determine if monitoring protease inhibitor plasma concentrations provides additional clinical benefit to the patient.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/06/20 alle ore 23:45:35